India’s Burmans Return To Trial Outsourcing With OneQuest
This article was originally published in PharmAsia News
The Burman family, formerly of India's Dabur Pharma, is considering a return to the medical business with its privately held company, OneQuest. The firm plans to provide molecular diagnostics for the world's major drug-research and outsourced clinical-trial companies in all therapeutic areas. OneQuest has been focusing its business on test services for oncological clinical trials. Sources say OneQuest also plans eventually to conduct trials itself. The diagnostics business used to be a part of Dabur Pharma, but was transferred to OneQuest before Fresenius Kabi bought Dabur. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?